The effect of terazosin and tolterodine on ureterl stent related symptoms

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201111255786N2

Enrollment

100

Registered

2012-03-04

Start date

2011-12-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral stent (Double-J stent) related symptoms. Calculus of kidney, Calculus of ureter, Calculus of kidney with calculus of ureter, Hydronephrosis with ureteropelvic junction obstruction

Interventions

Intervention 1: Group1: Placebo same as tolterodine and terazosin dose. Intervention 2: Group2: Terazosin 2mg BID. Intervention 3: Group3: Tolterodine 2mg Daily. Intervention 4: Group4: Tolterodine 2m

Placebo

Treatment - Drugs

Group1: Placebo same as tolterodine and terazosin dose

Group2: Terazosin 2mg BID

Group3: Tolterodine 2mg Daily

Group4: Tolterodine 2mg Daily + Terazosin 2mg BID

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Exclusion criteria:? ?1)?? ?Prior history of pelvic surgery? ? ?2) Prior history of Transurethral Resection of the either Prostate or Bladder Tumor ?3) Benign prostate hyperplasia? ?4) Recent or recurrent urinary tract infection ?5) Chronic medication with ?-blockers or Anti-cholinergic ?6) Pregnancy? ?7) Prostatitis ?8) Prostate cancer? ?9) Bilateral ureteroscopy or ureteral stenting? ?10) Age >18 and 20 mm? ?12) Diabetes? ?13??) Bladder Outlet Obstruction Inclusion criteria: If a patient dose not meet any exclusion criteria and to be undergone double-J stent indwelling.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lower Urinary Tract Symptoms. Timepoint: before intervention, 14days after intervention, stent removal time. Method of measurement: IPSS(International Prostate Symptom Score) and VAS(Visual Analogue Scale).	—

Secondary

Measure	Time frame
Drug complications. Timepoint: Stent removal time. Method of measurement: Getting history from patient.;Amount of analgesic consumption. Timepoint: Stent removal time. Method of measurement: Getting history from patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYousef Rezaei

Faculty of medicine, Urmia University of Medical Sciences

yousefrezaei1986@gmail.com+98 44 1223 4897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026